Announcements Trials
Browse Landscape

Phase

Phase NA 1Phase 2 1Phase 1 1

Status

Completed 3Withdrawn 1

Sponsor Class

OTHER 2NIH 1

Study Type

Interventional 3

Sponsor

Cancer Type

Thoracic 3Other neoplasm 1

Conditions

Lung Neoplasms 3Precancerous Conditions 1Carcinoma, Non-Small-Cell Lung 1

Interventions

Cyclophosphamide 1499Cisplatin 1435Paclitaxel 1340Radiotherapy 1310Carboplatin 1267Gemcitabine 1226Docetaxel 1133Bevacizumab 1070Fluorouracil 906Doxorubicin 805Dexamethasone 755Rituximab 744Capecitabine 735Oxaliplatin 709pembrolizumab 700Etoposide 679Irinotecan 639Filgrastim 624Cytarabine 587Nivolumab 586Leucovorin 583Vincristine 517Cetuximab 479Prednisone 478Bortezomib 474Trastuzumab 468Erlotinib Hydrochloride 467Surveys and Questionnaires 460Methotrexate 444Lenalidomide 436

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Completed × Iloprost × Clear all
NCT02237183 2023-11-28

Iloprost in Preventing Lung Cancer in Former Smokers

National Cancer Institute (NCI)

Phase 1 Completed
34 enrolled
Thoracic

Lung Neoplasms

NCT00084409 2020-05-14

Iloprost in Preventing Lung Cancer in Patients at High Risk for This Disease

University of Colorado, Denver

Phase 2 Completed
152 enrolled 18 charts
Other neoplasmThoracic

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Precancerous Conditions

NCT02784899 2018-06-20

Effect of Iloprost on Pulmonary Oxygenation in Patients With Low Diffusing Capacity During One-lung Ventilation

Yonsei University

Phase NA Completed
40 enrolled
Thoracic

Lung Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡